BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• Press Releases

  Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of SENS-401 for the Prevention of Cisplatin-Induced Ototoxicity

  March 7, 2025

   · 

  6 min read
• Press Releases

  Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

  March 7, 2025

   · 

  19 min read
• Press Releases

  New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences’ Dermatology Portfolio

  March 7, 2025

   · 

  8 min read
• Press Releases

  WBCIL Pioneers Liposomal APIs- Transforming Drug Delivery in Life Sciences

  March 7, 2025

   · 

  1 min read
• Press Releases

  Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

  March 7, 2025

   · 

  1 min read
• 

  Depression

  J&J Axes Late-Stage Depression Trial After Underwhelming Efficacy

  Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly given its recent $14.6 billion acquisition of Intra-Cellular Therapeutics and the success of Spravato for treatment-resistant depression.

  March 7, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025

  March 7, 2025

   · 

  1 min read
• 

  Regulatory

  Biogen, Eisai’s Leqembi Suffers Overseas Setbacks as UK Denies Coverage, Australia Denies Approval

  Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug not cost-effective.

  March 7, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Government

  Makary Shows Soft Support for FDA Vaccines Committee at Confirmation Hearing

  Analysts at Jefferies see Makary as a positive for the rare disease space, given his support for accelerated approvals and openness to “customizing regulatory pathways for rare diseases.”

  March 7, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Stomach cancer

  AstraZeneca Builds Stomach Cancer Case for Imfinzi With Strong Phase III Data

  Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The PD-L1 blocker brought in over $4.7 billion in sales last year.

  March 7, 2025

   · 

  2 min read

   · 

  Tristan Manalac